BioMedNewsBreaks Archive - Page 82 of 272

ThursdaySep 05, 2024 12:58 pm

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) CEO to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced participation at the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. According to the announcement, Bryan Kobel, CEO of TC BioPharm, will deliver a presentation providing an overview of the company’s business. To view the full press release, visit https://ibn.fm/17ZaO About TC BioPharm Holdings PLC TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the…

ThursdaySep 05, 2024 10:49 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced participation at the H.C. Wainwright 26th Annual Global Investment Conference. The conference, held virtually and in person, is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City. According to the announcement, Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will deliver a 30-minute company presentation on Tuesday, September 10, 2024, at 8 a.m. ET. Later that day, at 2 p.m. ET., Dr. Maccecchini will take part in…

WednesdaySep 04, 2024 3:33 pm

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Developing Fast-Track-Designated Treatment for Fibromyalgia

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, is developing TNX-102 SL, a new nonaddictive treatment for fibromyalgia, the prototypic nociplastic pain syndrome. According to a recent post, research into the causes and nature of pain is increasing; the post observed that there were more than 400 scientific presentations at the 2024 Word Congress on Pain, which was held Aug. 6–9, 2024, and was sponsored by the International Association for the Study of Pain. The article noted there different types of pain have been identified: nociceptive pain, neuropathic pain and nociplastic pain.…

WednesdaySep 04, 2024 3:25 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is slated for Sept. 9–11, 2024, in New York. According to the announcement, CEO John Climaco will present at the event; his presentation will be available as an on-demand video webcast beginning Sept. 9 at 7 a.m. ET. Climaco will also be available to participate in one-on-one meetings. To view the on-demand webcast, visit https://ibn.fm/gaP8o To view the full…

WednesdaySep 04, 2024 2:18 pm

BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has entered into a placement agency agreement. The agreement is for the purchase and sale of 8,106,584 shares of its common stock (or prefunded warrants in lieu thereof). The shares are offered at $0.55 per share (or $0.549 per prefunded warrant in lieu thereof). According to the announcement, the offering is expected to close on or about Sept. 5, 2024. Gross proceeds of the offering, which will be subject to customary closing conditions, are estimated to be approximately $4.45 million before deduction of…

WednesdaySep 04, 2024 1:55 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Releases Q2 Report, AVERSA Fentanyl Update

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, is reporting its Q2 2024 financial results for the period ending July 31, 2024. According to the report, the company ended the quarter in a strong cash position, reinforcing its ability to advance the development of its lead product, AVERSA(TM) Fentanyl, with a New Drug Application (“NDA”) submission planned for the first half of 2025. The report showed Nutriband with cash reserves of $6.75 million, supporting the company's ongoing development and commercialization efforts for AVERSA Fentanyl; total assets are valued at $13.63 million, with stockholders' equity amounting to $12.5 million. The…

WednesdaySep 04, 2024 1:39 pm

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Doses Five New Patients in UK ACHIEVE Phase 2b Trial

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has dosed five new patients in the ongoing ACHIEVE phase 2b trial in the United Kingdom. According to the announcement, that brings the total number of patients dosed to six; five patients have received a second dose and two patients have received a third dose. The announcement noted that there are four possible doses at the higher dose level, with each 5mL dose containing up to 230 million gamma delta T cells. New patients will continue to be identified, screened and enrolled into…

WednesdaySep 04, 2024 11:40 am

BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor

Telomir Pharmaceuticals (NASDAQ: TELO), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, today announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Dr. Angel’s extensive career in pharmaceutical innovation spans over 40 years, during which he has been instrumental in the research, development, and regulatory approvals of numerous therapies across various therapeutic areas. Dr. Angel will collaborate with Telomir’s senior management to expedite the pre-clinical and clinical path of Telomir-1, the company’s lead product candidate. According to the announcement, Dr. Angel will concentrate his scientific efforts on unveiling and experimentally…

TuesdaySep 03, 2024 2:09 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in the most recent episode of IBN’s BioMedWire Podcast. During the episode, CNS Pharmaceuticals CEO John Climaco talks with podcast host Carmel Fisher to explain what sets CNSP’s Berubicin and new TPI-287 candidate apart from anything else in development for glioblastoma. The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. “We are an oncology drug-development company,” said CNS Pharmaceuticals CEO John Climaco during the…

TuesdaySep 03, 2024 12:56 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K

PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, has entered into definitive agreements for the immediate exercise of certain outstanding warrants. The agreements outline the “purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 per share, at a reduced exercise price of $0.20 per share,” the company stated in the press release. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The announcement noted that PaxMedica will also issue new unregistered warrants to purchase…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) CEO to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Developing Fast-Track-Designated Treatment for Fibromyalgia

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference

BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Releases Q2 Report, AVERSA Fentanyl Update

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Doses Five New Patients in UK ACHIEVE Phase 2b Trial

BioMedNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search